当院における酸化マグネシウム製剤の使用状況調査

Abstract

酸化マグネシウム製剤の投与にあたっては，高Mg血症に注意する必要があり，入院患者の処方実態と血清Mgの測定状況を 調査した．1日服用量中央値は年齢別及び腎機能別で群間に差がなかった（ P=0.26，P=0.09）．血清Mg測定率は全群に比べ高 齢者群では大差がなく，腎機能低下群で増加傾向であった（全群11.9％，高齢者群11.3％，腎機能低下群22.9％）．また，高齢 かつeGFR 45 mL/min/1.73 m2未満では高Mg血症を来しやすいことが示唆され，この群における積極的な血清Mgの測定は，酸 化マグネシウム製剤の安全な使用に繋がると考えられた．

We investigated the state of magnesium oxide (MgO) prescription and the serum Mg levels of our inpatients since hypermagnesemia is high risk while MgO intake．Neither the median dose of daily MgO prescription to elderly patient group nor decreased kidney functional group show statistifically significant difference with all patients (P=0.26 and P=0.09)．The ratio of serum Mg measurements in elderly patient group (11.3%) was similar to that in all patients group (11.9%)，but was higher in decreased kidney functional group (22.9%)． It was suggested that the elderly patient group with eGFR value less than 45 mL/min/1.73m² has a high risk of hypermagnesemia．We therefore propose to measure the serum Mg levels of this high-risk group．